Why the study?
Recurrent vascular events occur in around 20% of cases within 3 months after acute cerebrovascular ischemia, and antiplatelet therapy may play a key role in minimizing this risk.
Does oral antiplatelet therapy (aspirin, clopidogrel, ticagrelor) prevent recurrent vascular events in patients with non-cardioembolic ischemic cerebrovascular events?
Does oral antiplatelet therapy (aspirin, clopidogrel, ticagrelor) prevent recurrent vascular events in patients with non-cardioembolic ischemic cerebrovascular events?
This review summarizes the current evidence for using aspirin, clopidogrel, and ticagrelor in the secondary prevention of non-cardioembolic stroke and TIA.
Answers are grounded in this paper and cite their sources.
Offers clinicians a reference for antiplatelet secondary prevention; leaves open comparative effectiveness gaps for researchers.
Stroke is the leading cause of disability and mortality worldwide. After an acute cerebrovascular ischemia, recurrent vascular events, including recurrent stroke or transient ischemic accidents (TIA), occur in around 20% of cases within the first 3 months. In order to minimize this percentage, antiplatelet therapy may play a key role in the management of non-cardioembolic cerebrovascular events. This review will focus on the current evidence of antiplatelet therapies most commonly discussed in practice guidelines and used in clinical practice for the treatment of stroke/TIA complications. The antiplatelet therapies most commonly used and discussed are as follows: aspirin, clopidogrel, and ticagrelor.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: